TOKYO-- Eisai will launch its treatment for Alzheimer's disease in China this July with a major health care provider there under plans announced Wednesday, entering the third market after Japan and the U.S.
Eisai expects revenue from lecanemab, sold under the brand name Leqembi, to reach 56.5 billion yen ($360 million) in the fiscal year ending March 2025.
